MedTrace Logo

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

NCT04613557 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-08-31

No results posted yet for this study

Summary

The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide

Conditions

  • Relapse/Refractory Multiple Myeloma

Interventions

BIOLOGICAL

CYAD-211

Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell

DRUG

Endoxan

Preconditioning chemotherapy

DRUG

Fludara

Preconditioning chemotherapy

Sponsors & Collaborators

  • Celyad Oncology SA

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-16
Primary Completion
2022-12-21
Completion
2037-02-28
FDA Drug
Yes

Countries

  • United States
  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04613557 on ClinicalTrials.gov